Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 

Invivyd (IVVD) granted stock options as inducement awards to six newly hired non-executive employees on September 1, 2026.

Rhea-AI Summary

Invivyd (IVVD) granted stock options as inducement awards to six newly hired non-executive employees on September 1, 2026.

The employees received options to purchase an aggregate of 255,000 shares of Invivyd common stock under the 2026 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a per share exercise price of $0.8799, equal to the closing price on the grant date, and a 10-year term. Each option vests over four years, with 25% vesting on the first anniversary of the employee’s start date and the remainder vesting in equal monthly installments thereafter, subject to continuous service.

News Explained

Invivyd has granted options covering 255,000 shares to six new employees; if the options are exercised, they could increase shares outstanding and dilute existing holders, subject to four-year vesting.

Market Context

The August 4 inducement-grant event saw IVVD move 3.92% higher over 24 hours. That historical compar...

Analysis

The August 4 inducement-grant event saw IVVD move 3.92% higher over 24 hours. That historical comparison adds context, while recent insider activity was net selling and the current announcement provides award terms.

Key Figures

Employees Granted Options: 6 employees Aggregate Shares: 255,000 shares Exercise Price: $0.8799 per share +3 more

6 metrics

Employees Granted Options 6 employees September 1, 2026 grant

Aggregate Shares 255,000 shares Employee stock options

Exercise Price $0.8799 per share Closing price on grant date

Vesting Period 4 years Subject to continuous employee service

Initial Vesting 25% Vests on the first anniversary of the employee's start date

Option Term 10 years Under the 2026 Inducement Plan

Historical Context

5 past events · Latest: Sep 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 01	Leadership change	Neutral	-7.8%	Chairman became CEO as VYD2311 results approached
Aug 13	Q2 earnings report	Neutral	+5.1%	Revenue growth coincided with higher expenses and increased net loss
Aug 04	Inducement grants	Neutral	+3.9%	Ten employees received options for 277,500 shares
Jul 06	EUA update	Negative	-6.7%	PEMGARDA EUA termination notice was received from FDA
Jul 02	Inducement grants	Neutral	+4.6%	Fourteen employees received options for 493,000 shares

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior inducement-grant announcements were followed by gains of 3.92% and 4.61%, while other recent news produced mixed reactions.

Key Terms

Nasdaq Listing Rule 5635(c)(4)

1 terms

Nasdaq Listing Rule 5635(c)(4) regulatory

"The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on September 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 255,000 shares of its common stock, each as a material inducement for each employee’s entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. 

The options have a per share exercise price of $0.8799, representing the closing price of Invivyd’s common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniversary of the employee’s start date and the remaining shares vesting in equal monthly installments thereafter, in each case, subject to the employee’s continuous service with Invivyd. The options have a 10-year term and are subject to the terms of the Invivyd, Inc. 2026 Inducement Plan. 

About Invivyd   

Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Visit https://invivyd.com/ to learn more.  

This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. 

Contacts: 

Media Relations 
(781) 208-0160 
media@invivyd.com 

Investor Relations 
(781) 208-1747 
investors@invivyd.com 

FAQ

What inducement grants did Invivyd (IVVD) announce on September 3, 2026?

Invivyd announced stock option grants to six newly hired non-executive employees, covering an aggregate of 255,000 shares of common stock as material inducement awards tied to their employment.

What are the key terms of the Invivyd (IVVD) inducement stock options?

The options have a per share exercise price of $0.8799, a 10-year term, and vest over four years: 25% on the first anniversary of each employee’s start date and the remainder in equal monthly installments, subject to continuous service.

Under what plan and Nasdaq rule were the Invivyd (IVVD) inducement options granted?

The inducement options were granted under the Invivyd 2026 Inducement Plan and structured in accordance with Nasdaq Listing Rule 5635(c)(4), which governs equity awards granted as a material inducement to employment.